Acquired hemophilia A · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Prednisolone monotherapy Variant #03 | — | R 109 | 84d | — | — | — | — | 1 |
Cyclophosphamide and Prednisone N/A - intrathecal component | — | R 93 | — | — | ~10.0 mo | — | — | 1 |
Rituximab monotherapy N/A - secondary systemic drug | — | R 52 | 180d | ~20.3 mo | — | ~4 | ~R 208 PFS proxy · indirect | 20 |
Prednisone monotherapy Variant #11 | — | R 22 | 7d | ~2.2 mo | ~14.1 mo | ~10 | ~R 215 PFS proxy · indirect | 8 |
Cyclophosphamide and Prednisolone Variant #01 | — | R 13 | — | — | — | — | — | — |
5 of 5 regimens shown